Response to adjuvant bevacizumab among patients with resected melanoma may vary by age

Source: EurekAlert!, October 2020

Younger patients with resected melanoma had some benefit from adjuvant treatment with the anti-VEGF therapeutic bevacizumab (Avastin) while older patients with resected melanoma did not.

Preclinical data showed that VEGF, a protein that promotes angiogenesis and is the target of bevacizumab, decreased with age, and was superseded by the protein sFRP2 in promoting angiogenesis.

Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research

READ THE ORIGINAL FULL ARTICLE